Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

Area of Science:

• Oncology
• Clinical Trials
• Cancer Therapeutics

Background:

• Early-stage non-small cell lung cancer (NSCLC) stages I-III typically undergo surgery, immunotherapy, and chemotherapy.
• Many clinical trials have excluded patients with specific genetic alterations like EGFR and ALK.
• Neoadjuvant therapy is emerging as a critical treatment modality for resectable NSCLC.

Purpose of the Study:

• To review completed clinical trials on neoadjuvant treatment for NSCLC.
• To discuss ongoing trials evaluating neoadjuvant EGFR-TKI monotherapy, chemotherapy, and immunotherapy combinations.
• To analyze the potential benefits, challenges, and future directions in neoadjuvant NSCLC therapy.

Main Methods:

• Literature review of completed clinical trials in neoadjuvant NSCLC treatment.
• Analysis of ongoing clinical trials focusing on EGFR-TKI, chemotherapy, and immunotherapy combinations.
• Discussion of emerging trends and future research avenues in neoadjuvant NSCLC therapy.

Main Results:

• Several completed trials have investigated neoadjuvant approaches for NSCLC.
• Ongoing trials are actively evaluating EGFR-TKI monotherapy, chemotherapy, and immunotherapy combinations.
• The field is rapidly advancing, with significant potential for improved patient outcomes.

Conclusions:

• Neoadjuvant therapy, particularly with targeted agents and immunotherapy, shows promise for early-stage NSCLC.
• Further research is needed to optimize treatment strategies and overcome challenges.
• Future directions include refining combination therapies and addressing patient populations with specific genetic alterations.